ID   CHO/CD44v3-10
AC   CVCL_D2RA
DR   Wikidata; Q127380492
RX   PubMed=36835416;
RX   PubMed=36975491;
RX   PubMed=37176118;
RX   PubMed=37185762;
RX   PubMed=37189717;
RX   PubMed=37218897;
RX   PubMed=37489367;
RX   PubMed=37504249;
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:1681; CD44 (Note=Isoform v3-10; with a N-terminal GLEGGVAMPGAEDDVV = PA16-tag).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
CC   Cell type: Epithelial cell of ovary; CL=CL_2000064.
OX   NCBI_TaxID=10029; ! Cricetulus griseus (Chinese hamster)
HI   CVCL_0214 ! CHO-K1
SX   Female
AG   Adult
CA   Spontaneously immortalized cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   PubMed=36835416; DOI=10.3390/ijms24044007; PMCID=PMC9965047;
RA   Ejima R., Suzuki H., Tanaka T., Asano T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 6 monoclonal antibody
RT   C44Mab-9 for multiple applications against colorectal carcinomas.";
RL   Int. J. Mol. Sci. 24:4007.1-4007.16(2023).
//
RX   PubMed=36975491; DOI=10.3390/cimb45030121; PMCID=PMC10047040;
RA   Suzuki H., Tanaka T., Goto N., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 4 monoclonal antibody
RT   C44Mab-108 for immunohistochemistry.";
RL   Curr. Issues Mol. Biol. 45:1875-1888(2023).
//
RX   PubMed=37176118; DOI=10.3390/ijms24098411; PMCID=PMC10179237;
RA   Suzuki H., Kitamura K., Goto N., Ishikawa K., Ouchida T., Tanaka T.,
RA   Kaneko M.K., Kato Y.;
RT   "A novel anti-CD44 variant 3 monoclonal antibody C44Mab-6 was
RT   established for multiple applications.";
RL   Int. J. Mol. Sci. 24:8411.1-8411.17(2023).
//
RX   PubMed=37185762; DOI=10.3390/cimb45040238; PMCID=PMC10137259;
RA   Tawara M., Suzuki H., Goto N., Tanaka T., Kaneko M.K., Kato Y.;
RT   "A novel anti-CD44 variant 9 monoclonal antibody C44Mab-1 Was
RT   developed for immunohistochemical analyses against colorectal
RT   cancers.";
RL   Curr. Issues Mol. Biol. 45:3658-3673(2023).
//
RX   PubMed=37189717; DOI=10.3390/biomedicines11041099; PMCID=PMC10136282;
RA   Suzuki H., Ozawa K., Tanaka T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 7/8 monoclonal antibody,
RT   C44Mab-34, for multiple applications against oral carcinomas.";
RL   Biomedicines 11:1099.1-1099.15(2023).
//
RX   PubMed=37218897; DOI=10.3390/antib12020031; PMCID=PMC10204397;
RA   Kudo Y., Suzuki H., Tanaka T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 5 monoclonal antibody
RT   C44Mab-3 for multiple applications against pancreatic carcinomas.";
RL   Antibodies (Basel) 12:31.1-31.16(2023).
//
RX   PubMed=37489367; DOI=10.3390/antib12030045; PMCID=PMC10366929;
RA   Suzuki H., Goto N., Tanaka T., Ouchida T., Kaneko M.K., Kato Y.;
RT   "Development of a novel anti-CD44 variant 8 monoclonal antibody
RT   C44Mab-94 against gastric carcinomas.";
RL   Antibodies (Basel) 12:45.1-45.17(2023).
//
RX   PubMed=37504249; DOI=10.3390/cimb45070333; PMCID=PMC10378409;
RA   Ishikawa K., Suzuki H., Kaneko M.K., Kato Y.;
RT   "Establishment of a novel anti-CD44 variant 10 monoclonal antibody
RT   C44Mab-18 for immunohistochemical analysis against oral squamous
RT   cell carcinomas.";
RL   Curr. Issues Mol. Biol. 45:5248-5262(2023).
//